HLX85 / Shanghai Henlius Biotech, Fosun Pharma - LARVOL DELTA

At this year’s AACR conference, Henlius will showcase seven early-stage innovative assets with first-in-class (FIC) or best-in-class (BIC) potential. (Henlius Press Release) - "These include...multiple novel ADC candidates developed based on proprietary platform Hanjugator, including the EGFR×cMET bispecific ADC HLX48, HER2 biparatopic ADC HLX49, ADAM9 ADC HLX402, and ALPP/ALPPL2 ADC HLX85."

Preclinical • Oncology